The first nanotechnology-enabled gene delivery system capable of efficiently penetrating the hard-to-breach mucus barrier shielding human airway and lung tissue…
Articles by Charles Moore
The U.S. Food and Drug Administration on Thursday, July 2 announced that it has approved the first cystic fibrosis treatment…
Jason van’t Slot — a 20-year-old South African — was born with Cystic Fibrosis, and after receiving a prognosis of…
Garden Grove, California based Novoteris, LLC has received $2.8 million in funding from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) to…
Boulder, Colorado based Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (CF), recently announced…
The five-year survival rate for Canadians with cystic fibrosis who have received a lung transplant is 67% and half of…
Internationally recognized Cystic Fibrosis expert and State University of New York at Buffalo clinical professor of pediatrics Drucy S. Borowitz,…
The lead drug candidate under development by Celtaxsys — an Atlanta, Georgia based clinical-stage development company focused on novel therapeutics…
The U.K. based Cystic Fibrosis Trust, a national charity that funds research into the disease and provides information and…
Dr. Ewa Goldys and research colleagues at the Centre for Nanoscale BioPhotonics (CNBP) at Macquarie University in…